drugset / Trial / NCT02277158
Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.
Phase 1
Unknown
18 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose and safety of S-1 plus radiotherapy for patients with rectal cancer
Timeline
- Start
- 2014-11
- Primary completion
- 2015-06
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1 | Small molecule | 50 mg/m2 | — |
| Subject | S-1 | Small molecule | 65 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg/m2 | — |
| Subject | S-1 | Small molecule | 90 mg/m2 | — |